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Mineral metabolism is altered early in the course of chronic kidney disease (CKD)1 as documented by ele-
vations in the serum concentrations of fibroblast growth fac-
tor-23 (FGF23) and parathyroid hormone (PTH) in 70% and 
30%, respectively, of patients with estimated glomerular filtra-
tion rate of 50 mL·min−1·1.73 m−2. The levels of both hormones 
continue to rise over time as CKD progresses, presumably to 
maintain normal concentrations of phosphate and calcium 
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in serum. In patients with CKD, elevated serum concentra-
tions of FGF23 are associated with mortality,2 progression 
of CKD,2,3 left ventricular hypertrophy,4,5 and cardiovascular 
events6,7 independently of phosphate, PTH, and a variety of 
demographic and other clinical factors.
Editorial see p 7 
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Among patients with end-stage renal disease receiving dial-
ysis, levels of FGF23 can be increased by 2 to 3 orders of mag-
nitude. Among patients with exceptionally high serum FGF23 
concentrations, higher levels remain associated with poorer sur-
vival8–10 and ventricular hypertrophy.11 In animal models, FGF23 
induces cardiomyocyte hypertrophy4 and acutely increases intra-
cellular free calcium with possible induction of arrhythmias,12 
suggesting a direct role in cardiovascular disease. High serum 
concentrations of phosphate, PTH, calcium, and 1,25 dihydroxy 
vitamin D (calcitriol) stimulate FGF23. Preliminary studies show 
that the calcimimetic cinacalcet lowers FGF23 in patients receiv-
ing dialysis.13,14 However, it is unknown whether therapies that 
may lower serum FGF23 concentrations improve outcomes. We 
examined this question in the Evaluation of Cinacalcet Therapy 
to Lower Cardiovascular Events (EVOLVE) trial. We hypoth-
esized that treatment with cinacalcet (Sensipar/Mimpara) would 
reduce serum FGF23 concentrations compared with baseline 
and that patients treated with cinacalcet who experienced a sig-
nificant reduction in FGF23 would experience fewer deaths and 
cardiovascular events than those whose serum FGF23 remained 
unchanged or increased.
Methods
Study Population and Design
A total of 3883 patients with secondary hyperparathyroidism (intact 
PTH ≥300 pg/mL) receiving hemodialysis were enrolled in the 
EVOLVE trial. The trial was designed to assess the benefits and risks 
of treatment with cinacalcet compared with placebo in addition to 
standard of care (calcitriol or vitamin D analogs and phosphate bind-
ers) on the primary composite end point of mortality and major car-
diovascular events (myocardial infarction, hospitalization for unstable 
angina, heart failure, or peripheral vascular event). Study design,15 
baseline characteristics,16 and primary results, including a CONSORT 
(Consolidated Standards of Reporting Trials) diagram,17 have previ-
ously been published. The trial was sponsored by Amgen Inc and was 
led by an academic Executive Committee with direct oversight of all 
final analyses and publications. The Executive Committee had full 
access to all of the data in the study and takes responsibility for the 
integrity of the data, the accuracy of the data analysis, and the writing 
of this report. Approval from ethics committees at all participating 
sites and informed consent from all patients were obtained.
During the trial, additional serum samples were obtained at pre-
specified visits in 394 of 467 sites. Serum FGF23 concentrations were 
measured from these stored samples by a Luminex-based microbead 
assay (HBNMAG-51K, Millipore, Billerica, MA) that uses poly-
clonal capture and detection antibodies. The levels with the Millipore 
assay were tightly correlated with levels by the Kainos intact assay 
(Figure I in the online-only Data Supplement) in internal validation 
studies performed at Amgen. The comparison revealed normal serum 
values for healthy adults (median) for serum FGF23 was 30 pg/mL 
(25th–75th percentile, 24–40 pg/mL) with the Kainos ELISA and 12 
pg/mL (25th–75th percentile, 8–42 pg/mL) with the Millipore assay. 
The Millipore assay demonstrated better overall percent recovery of 
human FGF23 spiked into human sera (80% versus 56% for 1 ng/
mL). The intra-assay coefficient of variation (the ratio of the standard 
deviation to mean) was 12% for both assays; the interassay coeffi-
cient of variation was 13% for Millipore and 7% for Kainos.
All other demographic and laboratory data analyzed were col-
lected with the primary EVOLVE trial.16–18 All end points were adju-
dicated by an independent Clinical Events Committee.
Statistical Analysis
As previously reported,17 the primary analysis of the main study (an 
unadjusted log-rank test using the intention-to-treat approach) did not 
reach significance. Among the goals of this post hoc analysis was 
the assessment of whether baseline serum FGF23 concentrations and 
changes in FGF23 concentrations in patients treated with cinacal-
cet were associated with death and major cardiovascular events as 
defined in the primary trial.
To test the associations among baseline serum FGF23 concen-
trations and the effect of reductions in FGF23 observed in patients 
treated with cinacalcet on outcomes, relative hazards and 95% con-
fidence intervals were calculated with Cox proportional hazards 
regression, stratified by country and diabetes status. The association 
of baseline FGF23 (week 0; log transformed) with outcomes was 
evaluated with multivariable Cox regression using a backward selec-
tion procedure. Other baseline variables evaluated in this model were 
those used in the multivariable regression analysis from the primary 
analyses.17 The analysis was performed on all patients with baseline 
serum FGF23 values, representing 77% of the original cohort.
To examine changes in FGF23, we identified a subset of patients 
who had serum from both weeks 0 and week 20 that allowed measure-
ment of FGF23 values. The 20-week time point was selected because 
91% of patients randomized to cinacalcet were still maintained on their 
original treatment assignment and the majority of patients had samples 
drawn at this time point. FGF23 values at weeks 0, 20 and 100 were 
summarized descriptively using the FGF23 cohort. We compared values 
between randomized treatment groups at week 20 using the Wilcoxon 
rank-sum test. We also generated Pearson correlation coefficients to 
assess the relation among changes in serum FGF23 and changes in 
plasma PTH, corrected serum calcium, and serum phosphate.
We examined the effect of changes in FGF23 from baseline to 
week 20 on subsequent outcomes within the groups randomized to 
cinacalcet or placebo using multivariable Cox regression analysis. 
Variables identified in a univariate analysis as possible confounders19 
(ie, if the variable changed the point estimate for FGF23 by >10% or 
was associated with the outcome) were included in the final model. 
We adjusted for baseline FGF23, sex, race, vascular access, smok-
ing, and week 20 covariates (age, blood pressure, dialysis vintage, 
previous medical history, the cumulative paricalcitol equivalent dose 
of vitamin D sterols, the Quételet index [body mass index], and per-
cent reduction from baseline in FGF23). We a priori considered a 
≥30% reduction in FGF23 to represent a meaningful decline because 
a ≥30% reduction in PTH has been used clinically to assess the effi-
cacy of pharmacological therapies used to treat secondary hyperpara-
thyroidism.20,21 We also examined associations with a ≥50% decline 
in FGF23 in patients randomized to the cinacalcet group. The propor-
tion of patients achieving these reductions were compared between 
the 2 treatment groups by use of a χ2 test.
Finally, aiming to understand the relations among change in 
FGF23 and changes in other biochemical measures of CKD–mineral 
bone disorder (MBD), we categorized patients into below target, 
within target, and above target categories for PTH, calcium, and phos-
phate on the basis of the Kidney Disease Outcomes Quality Initiative 
(K/DOQI) CKD-MBD guidelines22 at 20 weeks and determined the 
percent change in FGF23 for patients in each of these categories.
The analyses presented here are not adjusted for multiplicity, and 
we considered 2-tailed values of P<0.05 statistically significant in 
this post hoc analysis. We conducted all statistical analyses using 
SAS 9.3 (SAS Institute Inc, Cary, NC).
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Results
Baseline Serum FGF23 Levels Predict Mortality
Of the 3883 randomized patients, 2985 (77%) had base-
line serum FGF23 concentrations and 2602 (67%) had both 
baseline and week 20 values; the latter represents the week 
20 FGF23 cohort. Differences in baseline characteristics of 
patients in the original cohort,17 FGF23 baseline cohort, and 
week 20 FGF23 cohort were minor (Table 1). After adjustment 
for baseline characteristics in a multivariable Cox regression 
analysis, higher baseline serum FGF23 concentrations were 
associated with an increased risk of the primary composite 
end point of the EVOLVE trial (death or first myocardial 
infarction, hospitalization for unstable angina, heart failure, or 
peripheral vascular event; Table 2). Although higher baseline 
FGF23 concentrations were associated with death or major 
cardiovascular events, baseline FGF23 concentrations did not 
modify the effect of cinacalcet on death or major cardiovascu-
lar events [log(FGF23)×treatment interaction; P=0.75].
Cinacalcet Decreases Serum FGF23 Concentrations
Median baseline serum FGF23 concentrations were 5555  pg/mL 
(10th–90th percentiles, 600–19 380 pg/mL) and 5600 pg/mL 
(10th–90th percentiles, 570–19 380 pg/mL) in patients random-
ized to cinacalcet and placebo, respectively (P=0.86). At week 
20, FGF23 values were 2255 pg/mL (10th–90th percentiles, 
170–14 470 pg/mL) in cinacalcet-treated patients compared 
with 5580 pg/mL (10th–90th percentiles, 550–19710 pg/mL) in 
placebo-treated patients (P<0.001). Figure 1 shows the serum 
FGF23 concentrations in patients randomized to cinacalcet or 
placebo at baseline, week 20, and week 100, showing sustained 
suppression in patients randomized to cinacalcet. A significantly 
larger proportion of patients randomized to cinacalcet compared 
with placebo had a reduction in serum FGF23 ≥30% (64% ver-
sus 28%) or ≥50% (50% versus 15%; P<0.001 for both com-
parisons). The reduction in serum FGF23 in patients randomized 
to cinacalcet was observed regardless of whether patients also 
received calcitriol or other vitamin D sterols. The percent change 
in FGF23 correlated directly with the percent change in PTH 
(r=0.214, P<0.001), albumin-corrected serum calcium (r=0.378, 
P<0.001), and serum phosphate (r=0.519, P<0.001).
Reduction in FGF23 Is Associated With Reduced 
Cardiovascular Mortality and Morbidity
Characteristics of patients who did or did not achieve a 
≥30% reduction in FGF23 by randomized treatment group 
are shown in Table 3. Characteristics of patients who did or 
did not achieve a ≥50% reduction in FGF23 by randomized 
treatment group are shown in Table I in the online-only Data 
Supplement. As shown in Figure 2, among patients random-
ized to cinacalcet, a ≥30% reduction in serum FGF23 between 
baseline and week 20 was associated with a reduction in the 
relative hazard (after week 20) of the primary composite end 
point, cardiovascular mortality, sudden cardiac death, heart 
failure, and the tertiary cardiovascular composite end point 
(CV death, myocardial infarction, heart failure, and hospi-
talization for unstable angina). Follow-up time from baseline 
was 4.2 years (1.0–5.0 years) and from week 20 was 3.9 years 
(1.0–4.6 years). The associations among FGF23 reduction 
and all-cause mortality, classic atherosclerotic end points 
(myocardial infarction, unstable angina, peripheral vascu-
lar event, and stroke), fracture, and parathyroidectomy were 
not statistically significant. A ≥50% reduction in FGF23 in 
the patients randomized to cinacalcet showed similar results 
with a more pronounced association with the heart failure end 
point (Figure 3). Among patients randomized to placebo, a 
≥30% reduction in FGF23 in patients was not associated with 
a reduction in cardiovascular events compared with patients 
with a <30% reduction in FGF23 (Figure II in the online-only 
Data Supplement).
Association of PTH, Calcium, and Phosphate With 
FGF23 Reduction
To understand the interrelations among many of the biochemi-
cal parameters of CKD-MBD in patients with secondary 
hyperparathyroidism, we performed the following exploratory 
analysis. We categorized patients as below target, within target, 
or above target for PTH, calcium, and phosphate per the K/
DOQI guidelines and determined the percent change in FGF23 
within each group (Figure 4A and 4B). For the 3 measured 
parameters of mineral metabolism, values below the K/DOQI 
target range were associated with more pronounced reductions 
in FGF23 levels in patients randomized to cinacalcet.
Discussion
Cinacalcet is known to lower serum PTH while also lowering 
serum calcium. In the present study, we showed that cinacal-
cet also reduced serum FGF23, and this decrease was associ-
ated with lower risks of cardiovascular mortality and selected 
cardiovascular events, including heart failure and sudden 
death. Whether the observed associations in the present study 
were a direct effect of FGF23 or an indirect effect cannot 
be discerned. However, the observation was independent of 
demographic factors and comorbid conditions; reductions in 
serum PTH, calcium, or phosphate; and the cumulative dose 
of vitamin D sterols.
FGF23 is involved in the regulation of mineral metabolism, 
stimulating phosphaturia, decreasing the synthesis of 1,25 
dihydroxy vitamin D, and inhibiting PTH secretion. FGF23 is 
upregulated in response to 1,25 dihydroxy vitamin D, PTH, cal-
cium, and possibly phosphate. Therefore, the management of 
CKD-MBD is difficult in that the intended improvement of one 
parameter often leads to unwanted alterations in other param-
eters. Another randomized trial showed that cinacalcet, but not 
calcitriol, significantly lowered FGF23 even after account-
ing for changes in serum calcium and phosphate.23 We con-
ducted exploratory analyses to attempt to determine whether 
the FGF23 lowering in the present study was dependent on 
other known modifiers of FGF23 secretion. Figure 4 shows 
more pronounced reductions in FGF23 in patients with larger 
reductions of PTH, calcium, and phosphate, even to levels 
considered below target by K/DOQI.22 In patients with serum 
calcium concentrations above K/DOQI targets, because of 
either unremitting tertiary hyperparathyroidism or poor adher-
ence, randomization to cinacalcet resulted in very little FGF23 
lowering. In rodents with CKD, calcium treatment increases 
FGF23 but also lowers PTH.24 Thus, it is unclear whether the 
FGF23 lowering is directly mediated by calcium or indirectly 
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Table 1. Baseline Characteristics of Patients Overall and in the FGF23 Cohorts
Baseline Baseline and Week 20
Demographics
All Patients in Study
(n=3883)
Baseline  
FGF23 Cohort
(n=2985)
Not in Baseline 
FGF23 Cohort
(n=898)
Week 20  
FGF23 Cohort
(n=2602)
Not in Week  
20 FGF23 Cohort
(n=1281)
Age, y
  Median 55.0 54.0 56.0 54.0 56.0
  10th, 90th percentile 35.0, 73.0 34.0, 73.0 36.0, 74.0 35.0, 73.0 35.0, 74.0
Female sex, % 40.6 40.7 40.5 40.5 41.0
Race or ethnic group, %
  White 57.7 58.0 56.6 57.6 57.8
  Black 21.6 20.1 26.5 20.2 24.4
  Other 20.8 21.9 16.9 22.2 17.9
Body mass index, kg/m2
  Median 26.3 26.2 26.6 26.3 26.5
  10th, 90th percentile 20.5, 36.6 20.4, 36.5 20.8, 36.8 20.4, 36.6 20.7, 36.5
Dialysis, mo
  Median 45.3 46.7 39.2 47.2 41.1
  10th, 90th percentile 9.1, 145.9 9.4, 147.4 8.4, 135.1 9.5, 148.0 8.5, 134.2
Blood pressure, mm Hg
  Systolic
   Median 140 140 143 140 142
   10th, 90th percentile 110, 177 110, 176 116, 178 110, 176 114, 177
  Diastolic
   Median 80 80 80 80 80
   10th, 90th percentile 60, 100 60, 100 60, 99 60, 100 60, 100
Medical history
  History of diabetes mellitus, % 33.5 31.6 40.0 31.2 38.2
   Type 1 4.0 3.9 4.3 3.7 4.4
   Type 2 29.6 27.8 35.6 27.6 33.7
  History of cardiovascular disease, % 95.0 94.6 96.2 94.6 95.8
   Hypertension 92.1 91.5 94.1 91.6 93.2
   Heart failure 23.3 22.7 25.3 21.8 26.4
   Peripheral vascular disease 16.4 15.8 18.0 15.6 17.9
   CABG 7.4 7.3 8.0 7.0 8.3
   PCI 6.7 6.8 6.7 6.6 7.1
   Myocardial infarction 12.4 12.4 12.7 11.9 13.5
   Stroke 9.1 8.8 10.1 8.9 9.6
   Transient ischemic attack 4.5 4.3 5.1 4.3 4.8
   Amputation 6.4 5.9 8.1 5.9 7.6
   Atrial fibrillation 11.0 11.2 10.4 11.0 11.0
  History of parathyroidectomy, % 4.6 4.7 4.1 5.0 3.7
  History of fracture, % 19.8 19.5 20.7 19.6 20.3
Laboratory parameters
  iPTH, pg/mL
   Median 693 703 668 701 682
   10th, 90th percentile 363, 1694 370, 1734 341, 1538 367, 1751 354, 1588
  Corrected calcium, mg/dL
   Median 9.8 9.8 9.8 9.8 9.8
   10th, 90th percentile 9.0, 10.7 9.0, 10.7 9.0, 10.7 9.0, 10.7 9.0, 10.7
(Continued )
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  Phosphate, mg/dL
   Median 6.2 6.2 6.2 6.3 6.2
   10th, 90th percentile 4.9, 8.4 4.9, 8.4 4.9, 8.3 4.9, 8.4 4.9, 8.4
  Calcium×phosphate, mg2/dL2
   Median 60.7 60.8 60.4 60.8 60.5
   10th, 90th percentile 47.8, 81.9 47.8, 81.9 47.7, 81.8 47.9, 81.8 47.6, 82.2
  FGF23, pg/mL
   Median 5590 5590 NA 5590 NA
   10th, 90th percentile 580, 19 540 580, 19 540 NA, NA 590, 19 380 NA, NA
  25(OH) D, ng/mL
   Median 17 17 17 18 17
   10th, 90th percentile 8, 37 8, 37 8, 38 8, 37 8, 37
  1,25 (OH)
2 D, pg/mL
   Median 8.8 8.6 9.2 8.6 8.9
   10th, 90th percentile 4.9, 23.5 4.9, 23.3 4.9, 23.7 4.9, 23.4 4.9, 23.5
  Bone-specific alkaline phosphatase, μg/L
    Median 23.03 22.94 23.25 22.92 23.24
    10th, 90th percentile 11.51, 68.00 11.39, 70.21 11.87, 62.79 11.37, 69.16 11.75, 66.06
  Albumin, g/dL
   Median 3.7 3.7 3.6 3.7 3.7
   10th, 90th percentile 3.2, 4.1 3.2, 4.1 3.2, 4.1 3.2, 4.1 3.2, 4.1
  Cholesterol (mg/dL)
   Total
    Median 162 163 159 163 159
    10th, 90th percentile 115, 223 116, 224 114, 221 117, 223 114, 224
   LDL
    Median 86 87 84 87 84
    10th, 90th percentile 48, 138 48, 138 47, 138 49, 138 47, 140
  HDL
    Median 41 41 40 41 40
    10th, 90th percentile 27, 62 27, 62 28, 62 27, 62 28, 61
Medications, %
  Vitamin D use 59.5 59.7 58.9 60.1 58.3
   Vitamin D sterol 58.2 58.2 58.2 58.6 57.5
   Nutritional vitamin D 2.9 3.4 1.3 3.6 1.6
  Phosphate binder use 88.4 88.8 87.1 89.3 86.6
   Calcium-containing 53.1 53.8 50.9 54.8 49.7
   Non–calcium-containing 35.3 35.0 36.2 34.6 36.8
  β-Adrenergic antagonists 46.9 45.8 50.8 46.3 48.3
  ACE inhibitors/angiotensin II 
receptor blockers
43.8 43.1 46.1 43.3 44.7
  Antiplatelet agents 37.9 36.8 41.4 36.3 41.0
  Statins 32.5 30.6 38.6 30.5 36.5
  Erythropoietin 85.0 85.5 83.1 85.2 84.5
  Iron supplements 56.9 58.4 52.0 58.7 53.3
n is the number of randomized patients. Percentages are based on n. ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass graft; FGF23, 
fibroblast growth factor-23; HDL, high-density lipoprotein; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein; NA, not applicable; and PCI, percutaneous 
coronary intervention. 
Table 1. Continued
Baseline Baseline and Week 20
Demographics
All Patients in Study
(n=3883)
Baseline  
FGF23 Cohort
(n=2985)
Not in Baseline 
FGF23 Cohort
(n=898)
Week 20  
FGF23 Cohort
(n=2602)
Not in Week  
20 FGF23 Cohort
(n=1281)
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through PTH. Other studies demonstrated that lower serum cal-
cium resulted in lower serum FGF23 concentrations, thereby 
preventing FGF23 suppression of PTH secretion.25 The analy-
ses shown here are consistent with observations in rodents that 
calcium may be involved in the regulation of FGF23.
The FGF23 lowering by cinacalcet appeared to be related 
to reductions in predominantly nonatherosclerotic cardiovas-
cular events, with the most pronounced reduction in heart 
failure and sudden cardiac death events. The mechanisms by 
which a reduction in FGF23 or cinacalcet reduces the risks 
of heart failure and sudden cardiac death are likely multifac-
torial. First, FGF23 is a direct cardiotropic hormone, induc-
ing cardiomyocyte hypertrophy and cell signaling, consistent 
with activation of fetal (growth) pathways.4 Faul et al4 dem-
onstrated that progression of left ventricular hypertrophy was 
more pronounced in patients with CKD with higher serum 
FGF23 concentrations and that the change in serum FGF23 
predicted the magnitude of change in left ventricular mass. 
In the 5/6-nephrectomy rat model, treatment with the calci-
mimetic R-568 or enalapril improved cardiac fibrosis, and the 
effects were additive.26 In a small study of patients receiving 
hemodialysis, treatment with cinacalcet improved diastolic 
dysfunction and reduced left ventricular mass index.27 Second, 
cinacalcet may reduce cardiac and arterial calcification. In 
rodent models, treatment with a calcimimetic lowered heart 
calcium content compared with control animals, whereas cal-
cimimetic plus calcium did not.28 Other studies showed that 
calcimimetics reduced arterial calcification compared with 
calcitriol and paricalcitol.29,30 In a randomized trial of patients 
receiving hemodialysis, treatment with cinacalcet and low-
dose vitamin D compared with flexible doses of vitamin D 
alone slowed the progression of coronary artery calcification 
on electron-beam computed tomography, with nominally sig-
nificant changes as assessed with the volumetric method of 
Figure 1. Median (quartiles 1 and 
3) fibroblast growth factor-23 
(FGF23) values from baseline and 
weeks 20 and 100 (FGF23 cohort). 
The reduction of FGF23 with 
cinacalcet occurred within the first 
20 weeks and was maintained 
throughout the study. In the 
patients randomized to cinacalcet, 
91% were receiving study drug at 
20 weeks and 79% at 100 weeks. 
In the patients randomized to 
placebo, 3% of patients had been 
placed on commercial cinacalcet 
at 20 weeks and 13% at 100 
weeks.
Table 2. Multivariable Cox Regression Model on Time to Primary Composite End Point
Parameters Hazard Ratio (95% CI) P Value
Treatment (cinacalcet/placebo) 0.88 (0.79–0.98) 0.02
Baseline FGF23 per 1-SD increase (log-scale) 1.16 (1.10–1.23) <0.001
Age, y 1.03 (1.03–1.04) <0.001
Baseline serum albumin per 1-SD difference 0.84 (0.80–0.89) <0.001
History of peripheral vascular disease 1.37 (1.20–1.57) <0.001
Systolic blood pressure per 10 mm Hg 1.02 (1.00–1.05) 0.06
Dialysis vintage 1.01 (1.00–1.03) 0.01
History of heart failure 1.23 (1.08–1.39) <0.01
History of coronary artery disease 1.49 (1.30–1.70) <0.001
History of cardiac arrhythmia 1.30 (1.13–1.49) <0.001
History of valvular heart disease or angina 1.26 (1.11–1.43) <0.001
History of transient ischemic attack 1.28 (1.02–1.61) 0.03
History of dyslipidemia 0.87 (0.77–0.98) 0.02
Tobacco use (reference=never)
  Former 1.12 (0.99–1.26) 0.07
  Current 1.62 (1.40–1.88) <0.001
Baseline variables were included using backward elimination regression analysis. CI indicates confidence interval; and 
FGF23, fibroblast growth factor-23. 
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Table 3. Baseline Characteristics in Randomized Patients by Achievement of ≥30% Reduction in FGF23 From Baseline to Week 20
Placebo
(n=1264)
Cinacalcet
(n=1338)
Demographics
<30% Reduction
(n=910)
≥30%Reduction
(n=354) P Value
<30% Reduction
(n=477)
≥30%
Reduction
(n=861) P Value
Age, y 0.72 0.08
  Median 54.0 54.0 53.0 55.0
  10th, 90th percentile 35.0, 72.0 34.0, 74.0 32.0, 74.0 35.0, 74.0
Female sex, % 38.4 43.5 0.09 38.6 42.5 0.16
Race or ethnic group, % 0.45 0.53
  White 58.0 54.2 56.6 59.2
  Black 19.8 20.9 20.3 20.2
  Other 22.2 24.9 23.1 20.6
Body mass index, kg/m2 0.37 0.03
  Median 26.4 26.1 26.8 26.0
  10th, 90th percentile 20.7, 37.0 20.2, 36.0 20.5, 37.6 20.1, 35.9
Dialysis vintage, mo 0.06 <0.001
  Median 46.0 52.0 39.9 50.6
  10th, 90th percentile 9.7, 153.9 12.7, 139.4 7.3, 145.0 10.7, 147.9
Blood pressure, mm Hg
  Systolic 0.11 0.02
   Median 140 145 140 140
   10th, 90th percentile 110, 177 111, 180 111, 178 110, 174
  Diastolic 0.11 0.06
   Median 80 80 80 80
   10th, 90th percentile 60, 100 61, 100 60, 100 59, 98
Medical history
  History of diabetes mellitus, % 31.6 30.8 0.77 31.9 30.7 0.65
   Type 1 4.2 3.7 3.4 3.5
   Type 2 27.5 27.4 28.5 27.2
  History of cardiovascular 
disease, %
94.9 92.4 0.08 95.6 94.5 0.40
   Hypertension 92.2 89.5 0.13 90.6 92.3 0.26
   Heart failure 21.8 22.3 0.83 22.6 21.3 0.56
   Peripheral vascular disease 16.3 15.3 0.66 13.4 16.3 0.17
   CABG 7.6 6.2 0.40 6.5 7.1 0.69
   PCI 6.6 5.9 0.67 7.8 6.2 0.26
   Myocardial infarction 11.4 12.4 0.62 10.9 12.8 0.31
   Stroke 10.2 10.5 0.90 7.5 7.7 0.94
   Transient ischemic attack 4.1 3.4 0.59 6.1 3.9 0.08
   Amputation 6.4 5.9 0.77 5.0 5.8 0.55
   Atrial fibrillation 11.6 11.6 0.97 11.9 9.5 0.16
  History of parathyroidectomy, % 5.4 4.5 0.53 3.8 5.5 0.17
  History of fracture, % 21.6 18.6 0.24 18.9 18.1 0.74
Laboratory parameters
  PTH, pg/mL 0.35 <0.001
   Median 685 731 658 740
   10th, 90th percentile 364, 1678 373, 1835 360, 1523 376, 1951
  Corrected calcium (mg/dL) 0.34 0.18
   Median 9.8 9.7 9.7 9.8
   10th, 90th percentile 9.0, 10.8 9.0, 10.6 9.0, 10.8 9.0, 10.7
(Continued )
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  Phosphate (mg/dL) 0.20 0.66
   Median 6.2 6.3 6.2 6.3
   10th, 90th percentile 4.9, 8.4 5.0, 8.5 4.8, 8.5 5.0, 8.2
  Calcium×phosphate, mg2/dL2 0.12 0.54
   Median 60.3 61.8 60.9 60.8
   10th, 90th percentile 47.3, 82.1 49.4, 81.7 47.0, 82.3 48.9, 81.2
  FGF23, pg/mL 0.03 0.22
   Median 5305 6465 5710 5500
   10th, 90th percentile 530, 18 510 870, 21 680 340, 20 290 750, 18 910
  25 (OH) D, ng/mL 0.61 0.87
   Median 18 18 17 18
   10th, 90th percentile 8, 38 8, 37 8, 37 8, 38
1,25 (OH)2 D, pg/mL 0.64 0.04
   Median 9.1 8.3 9.5 8.2
   10th, 90th percentile 4.9, 22.3 4.9, 21.8 4.9, 25.0 4.9, 23.7
Bone-specific alkaline phosphatase, μg/L <0.001 <0.001
   Median 21.52 26.02 19.00 25.67
   10th, 90th percentile 10.99, 61.76 12.08, 79.20 10.79, 57.07 12.05, 88.98
Albumin, g/dL 0.78 0.25
   Median 3.7 3.7 3.6 3.7
   10th, 90th percentile 3.2, 4.1 3.2, 4.1 3.2, 4.1 3.2, 4.1
  Cholesterol, mg/dL
   Total 0.55 0.58
    Median 165 164 161 162
    10th, 90th percentile 117, 225 118, 223 115, 225 117, 221
   LDL 0.07 0.74
    Median 89 84 87 86
    10th, 90th percentile 52, 137 50, 138 48, 136 47, 139
   HDL 0.58 0.22
    Median 41 41 39 41
    10th, 90th percentile 28, 63 27, 65 27, 59 27, 62
Medications, %
  Vitamin D use 62.5 55.1 0.02 59.5 59.8 0.92
   Vitamin D sterol 61.0 52.3 <0.01 58.7 58.5 0.95
   Nutritional vitamin D 3.6 4.5 0.46 3.4 3.3 0.92
  Phosphate binder use 89.7 90.4 0.70 86.4 90.1 0.04
   Calcium-containing 54.8 55.4 55.1 54.2
   Non–calcium containing 34.8 35.0 31.2 35.9
  β-Adrenergic antagonists 46.3 39.8 0.04 48.6 47.6 0.72
  ACE inhibitors/angiotensin II 
receptor blockers
42.1 41.0 0.72 46.1 44.0 0.46
  Antiplatelet agents 34.8 37.9 0.32 36.7 37.0 0.90
  Statins 29.0 32.2 0.27 30.4 31.4 0.72
  Erythropoietin 83.8 84.2 0.88 86.0 86.6 0.73
  Iron supplements 57.6 56.2 0.66 60.2 60.0 0.97
 n is the number of randomized patients. Percentages are based on n. The Wilcoxon rank-sum test was used for continuous variables, and the χ2 test was used 
for categorical variables. ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass graft; FGF23, fibroblast growth factor-23; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention; and PTH, parathyroid hormone.
Table 3. Continued
Placebo
(n=1264)
Cinacalcet
(n=1338)
Demographics
<30% Reduction
(n=910)
≥30%Reduction
(n=354) P Value
<30% Reduction
(n=477)
≥30%
Reduction
(n=861) P Value
 at Yale University on July 8, 2015http://circ.ahajournals.org/Downloaded from 
Moe et al  Cinacalcet, FGF23, and Cardiovascular Disease  35
evaluation.31 Large-artery calcification will lead to arterial 
stiffness and increased afterload pressure, contributing to left 
ventricular hypertrophy. Third, elevated levels of FGF23 are 
associated with endothelial dysfunction.32 Finally, it remains 
possible that activation of the calcium-sensing receptor with 
cinacalcet has direct effects on left ventricular hypertrophy 
and arterial smooth muscle calcification.33,34 In isolated car-
diomyocytes, activation of the calcium-sensing receptor with 
increased extracellular calcium or a calcimimetic induced an 
increase in intracellular calcium and calcineurin/nuclear factor 
of activated T cells signaling, pathways known to be involved 
in arrhythmias and left ventricular hypertrophy.35 However, 
we cannot discern true mechanisms from this study; thus, the 
results must be considered hypothesis generating.
There are several strengths to these analyses, including 
the relatively large sample size (the randomized trial largest 
in size and longest in duration ever conducted in the hemo-
dialysis population); diverse patient population; broad range 
of severity of hyperparathyroidism; detailed clinical assess-
ment; allowing for adjustment by baseline demographic, clini-
cal, and laboratory variables; stringent control of the FGF23 
assay; and most important, independent adjudication of all 
major end points. There are also several important limitations. 
First, baseline and week 20 FGF23 values were not available 
Figure 2. Relative hazard (HR) of achieving a ≥30% reduction in fibroblast growth factor-23 (FGF23) from baseline to week 20 vs not 
achieving such a reduction on clinical outcomes (patients randomized to cinacalcet from FGF23 cohort). Stratified by history of diabetes 
mellitus and country and adjusted for baseline FGF23, sex, race, vascular access, smoking, and week 20 covariates (age, blood pressure, 
dialysis vintage, medical history, cumulative paricalcitol equivalent dose of vitamin D sterols, body mass index, and percent reduction 
from baseline in FGF23). Patients with missing covariates are excluded. Annualized event rates for patients with ≥30% versus <30% 
reduction: primary composite end point, 13.7 (95% confidence interval [CI], 12.4–15.0) vs 16.2 (95% CI, 14.4–18.2); all-cause mortality, 
9.6 (95% CI, 8.6–10.7) vs 10.2 (95% CI, 8.8–11.8); cardiovascular mortality, 4.6 (95% CI, 3.9–5.5) vs 6.2 (95% CI, 5.1–7.5); sudden death, 
1.9 (95% CI, 1.4–2.4) vs 3.0 (95% CI, 2.3–4.0); heart failure, 2.7 (95% CI, 2.1–3.3) vs 4.0 (95% CI, 3.1–5.1); and tertiary cardiovascular 
composite, 8.2 (95% CI, 7.3–9.3) vs 11.7 (95% CI, 10.1–13.4). 
Figure 3. Relative hazard of achieving a ≥50% reduction in fibroblast growth factor-23 (FGF23) from baseline to week 20 vs not achieving 
such a reduction on clinical outcomes (patients randomized to cinacalcet from FGF23 cohort). Stratified by history of diabetes mellitus 
and country and adjusted for baseline FGF23, sex, race, vascular access, smoking, and week 20 covariates (age, blood pressure, dialysis 
vintage, medical history, cumulative paricalcitol equivalent dose of vitamin D sterols, body mass index, and percent reduction from 
baseline in FGF23). Patients with missing covariates are excluded. Annualized event rates for patients with ≥50% vs <50% reduction: 
primary composite end point, 13.6 (95% confidence interval [CI], 12.2–15.1) vs 15.5 (95% CI, 14.0–17.1); all-cause mortality, 9.6  
(95% CI, 8.4–10.8) vs 10.1 (95% CI, 8.9–11.4); cardiovascular mortality, 4.6 (95% CI, 3.8–5.5) vs 5.8 (95% CI, 4.9–6.9); sudden death, 
1.7 (95% CI, 1.2–2.4) vs 2.8 (95% CI, 2.2–3.6); heart failure, 2.3 (95% CI, 1.7–3.1) vs 3.9 (95% CI, 3.2–4.9); and tertiary cardiovascular 
composite, 8.0 (95% CI, 6.9–9.3) vs 10.9 (95% CI, 9.6–12.3).
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in all trial participants, although clinical characteristics of 
patients with and without baseline and week 20 FGF23 data 
were similar. Second, we analyzed the change in FGF23 at 20 
weeks, whereas events occurred up to 5 years. Because more 
than two-thirds of patients discontinued study drug (with >1 
in 5 patients randomized to placebo placed on commercial 
cinacalcet),17 we elected not to examine outcomes based on 
changes in FGF23 beyond 20 weeks. Had fewer patients dis-
continued study drug or had a larger proportion of patients 
provided serum samples as the trial progressed, we might have 
been able to derive more precise estimates of the associations 
among FGF23 concentrations and outcomes, as well as the 
persistence of the FGF23-lowering effect of cinacalcet. The 
relatively small number of patients randomized to placebo 
who experienced ≥30% reduction in FGF23 and differences 
in cointerventions (eg, parathyroidectomy, changes in phos-
phate binder type or dose, changes in the provision or dose of 
calcitriol or vitamin D sterols) could explain why a significant 
reduction in events in these patients was not observed. Third, 
we cannot rule out a “healthy responder” effect. In other 
words, a sizable cinacalcet-induced decline in FGF23 could 
reflect factors associated with favorable outcomes for which 
we were unable to adjust. Finally, we arbitrarily chose a 30% 
reduction in FGF23 as representing a change that was clini-
cally meaningful on the basis of other studies of therapeutics 
to lower PTH. Additional studies are required to define the 
optimal FGF23 target reduction or target end value.
Conclusions
In this post hoc analysis of the EVOLVE trial, we confirmed 
the association between serum FGF23 and cardiovascu-
lar events and mortality in a large and diverse population of 
patients receiving hemodialysis with moderate to severe sec-
ondary hyperparathyroidism.17 We demonstrated an FGF23-
lowering effect of cinacalcet that far exceeded that observed in 
patients treated with placebo, along with conventional agents 
used to manage CKD-MBD (ie, phosphate binders and vita-
min D sterols). In roughly two thirds of patients randomized to 
cinacalcet, FGF23 declined by at least 30% (in roughly half, 
the decline was at least 50%). Finally, these sizable reductions 
in FGF23 were associated with lower risks of the primary 
composite end point, heart failure events, and sudden death.
Figure 4. Patients randomized to cinacalcet in 
the fibroblast growth factor-23 (FGF23) cohort. 
Exploratory analyses to examine the relationship 
of changes in parathyroid hormone (PTH), calcium, 
and phosphate levels from baseline to week 20 
with change in FGF23. The bar graphs represent 
the median (quartiles 1 and 3) for percent change 
in FGF23 in patients who achieved PTH, calcium, 
and phosphate levels below, within, or above 
2003 National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative targets at 20 weeks of 
treatment with cinacalcet (A) or placebo (B).
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Drs Wheeler and Herzog; Mitsubishi: Dr Wheeler; MRC: 
Dr Wheeler; Otsuka: Dr Wheeler; Pfizer: Drs Mahaffey, Correa-
Rotter; Reata Pharmaceuticals: Drs Chertow and Correa-Rotter; 
Relypsa: Dr Herzog; Roche: Dr Correa-Rotter; Sandoz: Dr London; 
Sanofi: Dr Wheeler; Satellite Healthcare: Dr Chertow; Shire: 
Drs Floege, London, and Wheeler; UCB Celltech: Dr Wheeler; UCL: 
Dr Wheeler; Vifor: Drs Floege and Wheeler; ZS Pharma: Drs Herzog 
and Wheeler. Employees and stock holders of Amgen: Drs Dehmel, 
Goodman, Kubo, and Stolina.
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CLINICAL PERSPECTIVE
The results of this study suggest an important kidney-bone-cardiovascular link. Fibroblast growth factor-23 (FGF23) is 
made in the bone in response to elevated parathyroid hormone and 1,25(OH)2-vitamin D and increased dietary intake of 
phosphorus. FGF23 binds to its receptor and klotho coreceptor in the kidney to increase urinary phosphate and to decrease 
1,25(OH)2-vitamin D synthesis and in the parathyroid gland to reduce parathyroid hormone secretion as part of a negative 
feedback loop. In animals, FGF23 directly induces cardiac hypertrophy in a klotho-independent manner. Levels of FGF23 
increase with progressive kidney disease and, by the time a patient reaches dialysis, can be 100-fold greater than in individu-
als without kidney disease. The present study, a secondary analyses of the Evaluation of Cinacalcet HCl Therapy to Lower 
Cardiovascular Events (EVOLVE) trial, which randomized patients receiving hemodialysis to cinacalcet versus placebo for 
the treatment of secondary hyperparathyroidism, demonstrates that cinacalcet reduces serum FGF23 levels. Furthermore, in 
patients randomized to cinacalcet, a ≥30% decrease in FGF23 was associated with a reduction in mortality, heart failure, and 
nonatherosclerotic cardiovascular events, including sudden cardiac death. The latter is the leading cause of cardiovascular 
death in patients undergoing hemodialysis. The present study is the first to demonstrate that a reduction in FGF23 in patients 
receiving cinacalcet is associated with a reduction in hard clinical end points. It is important to emphasize that this is a sec-
ondary analyses and that the mechanisms by which a reduction in FGF23 or cinacalcet reduces the risks of heart failure and 
sudden cardiac death are likely multifactorial and cannot be discerned by this study.
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Supplementary Table 1.  Baseline characteristics of the cinacalcet 
patients by achievement of 50% reduction in FGF23 at week 20  
Demographics 
<50% 
Reduction 
(N=673) 
≥50%  
Reduction 
(N=665) 
    
Age (yr)   
 Median  54.0 56.0  
 (p10, p90) 33.0, 74.0 35.0, 74.0 
    
Female sex – (%) 37.3 45.0 
    
Race or ethnic group – (%)   
 White 57.9 58.6 
 Black 20.7 19.8 
 Other 21.4 21.5 
   
Body-mass index (kg/m2)   
 Median 26.5 26.0 
 (p10, p90) 20.4, 37.4 20.1, 35.9 
    
Dialysis vintage (months)   
 Median  41.6 51.4 
 (p10, p90) 8.0, 140.1 9.7, 153.3 
    
Blood pressure (mm Hg)   
 Systolic   
  Median  140 140 
  (p10, p90) 110, 178 110, 172 
 Diastolic   
  Median  80 80 
  (p10, p90) 60, 100 59, 98 
    
Medical History   
   
History of diabetes – (%) 30.8 31.4 
 Type 1 3.0 3.9 
 Type 2 27.8 27.5 
    
History of cardiovascular disease – (%) 95.1 94.7 
 Hypertension 90.6 92.8 
 Heart failure 22.6 20.9 
 Peripheral vascular disease 13.7 16.8 
 CABG 7.0 6.8 
 PCI 6.4 7.1 
 Myocardial infarction 11.1 13.1 
 Stroke 7.9 7.4 
 Transient ischemic attack  5.6 3.8 
 Amputation 5.1 6.0 
 Atrial fibrillation 11.4 9.3 
    
History of parathyroidectomy – (%) 4.8 5.0 
   
History of fracture – (%) 19.8 17.0 
    
Laboratory parameters   
    
iPTH (pg/mL)   
 Median  660 772 
 (p10, p90) 358, 1551 379, 1975 
    
Corrected calcium (mg/dL)   
 Median  9.7 9.8 
 (p10, p90) 9.0, 10.7 10.7 
    
Phosphorus (mg/dL)   
 Median  6.3 6.2 
 (p10, p90) 4.9, 8.6 5.0, 8.1 
    
Ca x P (mg2/dL2)   
 Median  61.3 60.6 
 (p10, p90) 47.5, 83.5 49.0, 79.6 
    
FGF23 (pg/mL)   
 Median  6190 5240 
 (p10, p90) 380, 21250 790, 17690 
    
25(OH)2D (ng/mL)    
 Median  17 18 
 (p10, p90) 8, 38 8, 37 
    
1,25 (OH) D (ng/L)   
 Median  8.8 8.4 
 (p10, p90) 4.9, 24.5 4.9, 24.6 
    
Bone-specific alkaline phosphatase 
(µg/L) 
  
 Median  19.94  27.29  
 (p10, p90) 10.63, 55.38 12.74, 99.68 
    
Albumin (g/dL)   
 Median  3.6 3.7 
 (p10, p90) 3.2, 4.1 3.2, 4.1 
    
Cholesterol (mg/dL)    
 Total    
  Median  162 162 
  (p10, p90) 113, 227 119, 220 
     
 LDL   
  Median  87 86 
  (p10, p90) 46, 140 48, 137 
     
 HDL   
  Median  39 42 
  (p10, p90) 27, 59 27, 63 
    
Medications (%)   
   
Vitamin D use 60.3 59.1 
 Vitamin D sterol 59.6 57.6 
 Nutritional vitamin D 3.3 3.3 
    
Phosphate binder use 87.1 90.5 
 Calcium-containing 56.5 52.6 
 Non-calcium containing 30.6 37.9 
    
Beta-adrenergic antagonists 48.4 47.5 
   
ACE-inhibitors/Angiotension receptor 
blockers 
45.9 43.6 
    
Anti-platelet agents 35.8 38.0 
   
Statins  28.5 33.5 
   
Erythropoietin  86.2 86.6 
   
Iron supplements  60.8 59.4 
    
N = Number of randomized subjects.  Percentages are based on N. 
 
Supplemental Figures: 
Figure 1 Legend:  Comparison of FGF23 levels (pg/ml) in samples from 50 patients on 
hemodialysis analyzed by the Millipore assay and the Kainos assay demonstrating 
strong correlation.  
Figure 2:  Relative Hazard of Achieving a ≥30% Reduction in FGF23 from Baseline to 
Week 20 versus not Achieving Such a Reduction on Clinical Outcomes (Patients 
Randomized to Placebo from FGF23 cohort). Stratified by history of diabetes and country, 
adjusted for baseline FGF23, sex, race, vascular access, smoking and week 20 covariates (age, 
blood pressure, dialysis vintage, prior medical history, cumulative paricalcitol equivalent dose of 
vitamin D sterols, BMI and percent reduction from baseline in FGF23).   
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